Cambridge-based biopharma company Ultivue has secured $22 million in Series C funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced June 14 and led by Northpond Ventures.
According to its Crunchbase profile, "Ultivue is an early stage life sciences tools company that seeks to provide the ultimate view into biology. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that vastly improve our understanding of biology and medicine."
The four-year-old startup has raised three previous funding rounds, including a $20 million Series B round in 2018.
The round brings total funding raised by Cambridge companies in science and engineering over the past month to $152 million. The local science and engineering industry has produced 95 funding rounds over the past year, securing a total of $4.4 billion in venture funding.
In other local funding news, biotechnology company Vaxess Technologies announced an $8.2 million Series A funding round on June 28.
According to Crunchbase, "Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world."
Founded in 2012, the company has raised 13 previous rounds, including a $650,000 grant in 2018.